AstraZeneca to expand its Sydney facility
Pharmaceutical giant AstraZeneca will spend $100 million expanding its Sydney facility, a move it says will add 60 jobs and boost exports to more than $2.4 billion over the next four years.
The company said the investment would fund three specialised production lines at the North Ryde facility for innovative respiratory medicines. AstraZeneca has invested $105m at the facility in the last five years. The three new specialised production lines are in addition to eight existing specialised lines at the site.
Melbourne-based specialist machine designers Andrew Donald Design Engineering will build each new production line and the machines will take a team of 36 people over 12 months to produce. Each production line has the capacity to produce over 70 million units per year of Pulmicort Respules, a medicine for patients with asthma. The medicine is produced in Australia for export markets, including China. It is predicted that by 2025 AstraZeneca’s site will be producing over one billion respules.